Collectively, these data support a model in which following CH treatment distinct effectors, Myc and β‐catenin, act in parallel to ensure that Tcf7l1 function is rapidly extinguished, permitting robust activation of FoxA2 in the presence of Nodal/Activin. The gene discussed is MYC; the disease is cyclic hematopoiesis.